In developing Lumerah™, a noninvasive sensor technology that directly measures fetal oxygen levels, Raydiant Oximetry aims to profoundly reduce the rising mortality and morbidity rates among mothers and babies during childbirth.
For the past 50 years, electronic fetal monitoring has been associated with a 6-fold increase in cesarean delivery in the US without any evidence that it reduces the rate of neonatal neurologic injury, stillbirth or cerebral palsy. Obstetrical providers need a more reliable tool to evaluate fetal oxygenation.
“The U.S. has the worst rate of maternal deaths in the developed world.”
NINA MARTIN, NPR
Current cesarean delivery rate in the US. C-sections are the world's most commonly performed surgery and in the US there are over 3,000 performed every day.1,2
The percentage of cesarean deliveries in US that are performed out of concern for fetal well-being.3,4,5
It is estimated that 84% of laboring women will experience a Category II fetal heart rate tracing or a nonreassuring fetal heart rate tracing during childbirth.6
Fetal pulse oximetry has been shown to reduce C-section rates for suspected fetal distress by 50%.7
In a bid to provide healthcare professionals with a more accurate method to to evaluate fetal oxygenation, Raydiant Oximetry is developing Lumerah™, a noninvasive fetal pulse oximeter.Invest in Lumerah
Preclinical trials indicate that Lumerah™ significantly improves sensitivity and specificity when detecting fetal distress.
Lumerah™ will be offered at an affordable price point selected in order to create a new standard of care that is accessible to all.
Lumerah™ grants healthcare professionals greater insight and confidence when making decisions during labor and delivery.
The FDA has already assigned Lumerah™ ‘Breakthrough Device’ status in order to fast-track its market approval.
The funding was led by Avestria Ventures, which invests in early-stage women’s health companies, and syndicated by KOFA Healthcare, V-Capital, Band of Angels, FemHealth Ventures, RHIA Ventures, SteelSky Ventures and Tri-Valley Ventures.Read more
Raydiant Oximetry, a Fogarty Innovation graduate, is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth and recently received a grant from the government of Ireland for approximately $3 million.Read more
Raydiant Oximetry, a Fogarty Institute company that is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth, has closed a $5.6 million Series A funding round led by VCapital.Read more
The accelerated path to approval through the breakthrough device program will enable better care to millions of mothers and babies during childbirth.Read more